Prime Medicine, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Prime Medicine is a pre-commercial biotechnology company developing Prime Editing gene-editing therapies. It reported 18 investigational programs across four strategic indication categories. The interim financial statements are unaudited.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | No product revenue reported | No product revenue reported | No product revenue reported | No product revenue reported |
| Research and development expense | $34.6 million | $18.9 million | $65.5 million | $32.6 million |
| General and administrative expense | $10.7 million | $7.4 million | $19.8 million | $13.6 million |
| Total operating expenses | $45.3 million | $26.3 million | $85.3 million | $46.2 million |
| Net loss | $42.4 million | $29.3 million | $81.8 million | $53.2 million |
| Net loss per share, basic and diluted | $0.47 | $1.76 | $0.91 | $3.31 |
There is no meaningful revenue margin to report because the company has not generated product revenue. Other income was $2.9 million in Q2 and $3.3 million for the first half of 2023, primarily reflecting interest income, partly offset for the six-month period by a decline in the fair value of the related-party Beam investment.
At June 30, cash and cash equivalents were $120.6 million, short-term investments were $87.0 million, and restricted cash was $13.5 million. Cash, cash equivalents, and investments totaled $207.6 million excluding restricted cash. Total assets were $280.9 million; total liabilities were $40.8 million, including operating lease liabilities. The filing reports no borrowings or other debt. Stockholders’ equity was $240.1 million, and accumulated deficit was $375.0 million.
For the six months ended June 30, operating cash use was $82.4 million, investing activities provided $15.2 million, and financing activities provided $0.1 million. Cash, cash equivalents, and restricted cash decreased by $67.0 million to $134.1 million.
Material changes versus the prior comparable period
- Six-month operating expenses rose $39.1 million, with R&D increasing $32.9 million and G&A increasing $6.2 million. Management attributed R&D growth principally to lab supplies, personnel, consultants, and expanded facilities, alongside continued discovery and IND-enabling work.
- Six-month net loss widened by $28.6 million. Higher operating costs were partly offset by improved other income versus 2022, including higher interest income and a smaller fair-value loss on the Beam investment.
- Operating cash use increased by $11.4 million year over year. The company’s cash, cash equivalents, and investments declined from $226.8 million at December 31, 2022 to $207.6 million at June 30, 2023.
Outlook, risks, and unusual items
- No revenue or earnings guidance was provided. The company expects significant operating losses and negative operating cash flows for the foreseeable future, with R&D spending expected to increase as programs progress toward preclinical and clinical development.
- The liquidity disclosures give two runway statements: the financial-statement note says available cash, cash equivalents, and investments should fund operations for at least the next 12 months from issuance; MD&A says existing resources are expected to fund operations and capital needs into 2025. Management cautions that assumptions may prove wrong and additional funding will be needed.
- Additional funding may come from equity, debt, collaborations, or licensing. Equity financing could dilute shareholders; debt may impose restrictive covenants; collaborations or licenses could require relinquishing valuable rights.
- In April 2023, the company amended its Cambridge lease for additional space, with approximately $3.7 million of rent over a 23-month term. A separate 60 First Street lease is expected to commence in Q1 2024; the company expects to pay up to approximately $208.7 million over its ten-year term, subject to lease credits. That lease had not commenced and was excluded from reported lease liabilities.
- The company gave Myeloid Therapeutics notice of its intent to terminate a collaboration agreement during Q2; $0.3 million of related license fees remained accrued. It also holds a related-party Beam equity investment valued at $6.4 million at June 30.
- Key risks include clinical and technical development, manufacturing, regulatory approval, competition, intellectual-property protection, reliance on third parties, retaining personnel, and access to capital. The filing says there were no material changes to previously reported risk factors and no legal proceedings considered probable to have a material adverse effect.
Important facts for investors to verify
- Reconcile the stated runway through at least 12 months with the MD&A estimate of funding into 2025, and assess the assumptions underlying both.
- Track cash burn against the $207.6 million of cash, cash equivalents, and investments, including the pace of R&D spending and any financing needs.
- Monitor preclinical and IND-enabling progress, clinical-trial timing, and the company’s ability to demonstrate Prime Editing’s safety and efficacy.
- Assess the future cost and commencement of the 60 First Street lease and its effect on long-term liquidity.
- Follow the Myeloid collaboration termination process, the Beam related-party investment, and any resulting financial or strategic effects.